Nath Bio-Genes Intrinsic Value
NATHBIOGEN Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹67.20 | ₹53.76 - ₹80.64 | -55.5% | EPS: ₹5.60, Sector P/E: 12x |
| Book Value Method | asset | ₹338.95 | ₹305.06 - ₹372.85 | +124.4% | Book Value/Share: ₹338.95, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹80.84 | ₹72.76 - ₹88.92 | -46.5% | Revenue/Share: ₹101.05, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹101.05 | ₹90.94 - ₹111.16 | -33.1% | EBITDA: ₹32.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹77.93 | ₹62.34 - ₹93.52 | -48.4% | CF Growth: 1.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹45.31 | ₹40.78 - ₹49.84 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹46.14 | ₹41.53 - ₹50.75 | -69.5% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹206.66 | ₹185.99 - ₹227.33 | +36.8% | EPS: ₹5.60, BVPS: ₹338.95 |
Want to compare with current market value? Check NATHBIOGEN share price latest .
Valuation Comparison Chart
NATHBIOGEN Intrinsic Value Analysis
What is the intrinsic value of NATHBIOGEN?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Nath Bio-Genes (NATHBIOGEN) is ₹80.84 (median value). With the current market price of ₹151.04, this represents a -46.5% variance from our estimated fair value.
The valuation range spans from ₹45.31 to ₹338.95, indicating ₹45.31 - ₹338.95.
Is NATHBIOGEN undervalued or overvalued?
Based on our multi-method analysis, Nath Bio-Genes (NATHBIOGEN) appears to be trading above calculated value by approximately 46.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 40.59 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.59 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 1.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 9.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.19x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Nath Bio-Genes
Additional stock information and data for NATHBIOGEN
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹18 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹75 Cr | ₹62 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹38 Cr | ₹37 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹17 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |